Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Sumi Biswas"'
Autor:
Kuang-Ting Ko, Frank Lennartz, David Mekhaiel, Bora Guloglu, Arianna Marini, Danielle J. Deuker, Carole A. Long, Matthijs M. Jore, Kazutoyo Miura, Sumi Biswas, Matthew K. Higgins
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Pfs48/45, a surface protein of Plasmodium falciparum, is a promising anti-malarial vaccine candidate whose structure is not entirely resolved. Here, the authors present the structure of the full-length molecule, and characterise the binding and activ
Externí odkaz:
https://doaj.org/article/1355932f57d3418087395ce9a33cabbe
Autor:
Angela M. Minassian, Yrene Themistocleous, Sarah E. Silk, Jordan R. Barrett, Alison Kemp, Doris Quinkert, Carolyn M. Nielsen, Nick J. Edwards, Thomas A. Rawlinson, Fernando Ramos Lopez, Wanlapa Roobsoong, Katherine J.D. Ellis, Jee-Sun Cho, Eerik Aunin, Thomas D. Otto, Adam J. Reid, Florian A. Bach, Geneviève M.C. Labbé, Ian D. Poulton, Arianna Marini, Marija Zaric, Margaux Mulatier, Raquel Lopez Ramon, Megan Baker, Celia H. Mitton, Jason C. Sousa, Nattawan Rachaphaew, Chalermpon Kumpitak, Nongnuj Maneechai, Chayanut Suansomjit, Tianrat Piteekan, Mimi M. Hou, Baktash Khozoee, Kirsty McHugh, David J. Roberts, Alison M. Lawrie, Andrew M. Blagborough, Fay L. Nugent, Iona J. Taylor, Kimberly J. Johnson, Philip J. Spence, Jetsumon Sattabongkot, Sumi Biswas, Julian C. Rayner, Simon J. Draper
Publikováno v:
JCI Insight, Vol 6, Iss 23 (2021)
Controlled human malaria infection (CHMI) provides a highly informative means to investigate host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of new drugs and vaccines. However, unlike Plasmodium falciparum, well-charac
Externí odkaz:
https://doaj.org/article/8f5efdb3fb3a46f088a6c09f41c0d102
Autor:
Marija Zaric, Arianna Marini, Carolyn M. Nielsen, Gaurav Gupta, David Mekhaiel, Thao P. Pham, Sean C. Elias, Iona J. Taylor, Hans de Graaf, Ruth O. Payne, Yuanyuan Li, Sarah E. Silk, Chris Williams, Adrian V. S. Hill, Carole A. Long, Kazutoyo Miura, Sumi Biswas
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Plasmodium falciparum transmission-blocking vaccines (TBVs) targeting the Pfs25 antigen have shown promise in mice but the same efficacy has never been achieved in humans. We have previously published pre-clinical data related to a TBV candidate Pfs2
Externí odkaz:
https://doaj.org/article/f21e9455de774a698a42b7af607f559b
Autor:
Hans de Graaf, Ruth O. Payne, Iona Taylor, Kazutoyo Miura, Carol A. Long, Sean C. Elias, Marija Zaric, Angela M. Minassian, Sarah E. Silk, Lee Li, Ian D. Poulton, Megan Baker, Simon J. Draper, Diane Gbesemete, Nathan J. Brendish, Filipa Martins, Arianna Marini, David Mekhaiel, Nick J. Edwards, Rachel Roberts, Johan Vekemans, Sarah Moyle, Saul N. Faust, Eleanor Berrie, Alison M. Lawrie, Fergal Hill, Adrian V. S. Hill, Sumi Biswas
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
BackgroundTransmission blocking vaccines targeting the sexual-stages of the malaria parasite could play a major role to achieve elimination and eradication of malaria. The Plasmodium falciparum Pfs25 protein (Pfs25) is the most clinically advanced ca
Externí odkaz:
https://doaj.org/article/daf9bdd8e4a1400a9c2b0c0584c0a152
Autor:
Daniel Wright, Elizabeth R. Allen, Madeleine H.A. Clark, John N. Gitonga, Henry K. Karanja, Ruben J.G. Hulswit, Iona Taylor, Sumi Biswas, Jennifer Marshall, Damaris Mwololo, John Muriuki, Bernard Bett, Thomas A. Bowden, George M. Warimwe
Publikováno v:
iScience, Vol 23, Iss 11, Pp 101669- (2020)
Summary: Rift Valley fever (RVF) is a viral hemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following RVF virus (RVFV) infection and that this correlates with acqui
Externí odkaz:
https://doaj.org/article/a0c1c18735e34b9c8e2bc08665f601f0
Autor:
Frank Lennartz, Florian Brod, Rebecca Dabbs, Kazutoyo Miura, David Mekhaiel, Arianna Marini, Matthijs M. Jore, Max M. Søgaard, Thomas Jørgensen, Willem A. de Jongh, Robert W. Sauerwein, Carole A. Long, Sumi Biswas, Matthew K. Higgins
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-11 (2018)
Pfs48/45 is a promising component for a transmission-blocking malaria vaccine. Here, the authors develop a system to produce full-length Pfs48/45 for immunisation, characterise a panel of monoclonal antibodies and determine the structure of a potent
Externí odkaz:
https://doaj.org/article/3e590003190943eebd4a943c9cadaa5a
Autor:
Arianna Marini, Yu Zhou, Yuanyuan Li, Iona J. Taylor, Darren B. Leneghan, Jing Jin, Marija Zaric, David Mekhaiel, Carole A. Long, Kazutoyo Miura, Sumi Biswas
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Development of effective malaria vaccines requires delivery platforms to enhance the immunogenicity and efficacy of the target antigens. This is particularly challenging for transmission-blocking malaria vaccines (TBVs), and specifically for those ba
Externí odkaz:
https://doaj.org/article/b455bad731d24a199302dd720d7e9e80
Autor:
Anais Bompard, Dari F. Da, Rakiswendé S. Yerbanga, Sumi Biswas, Melissa Kapulu, Teun Bousema, Thierry Lefèvre, Anna Cohuet, Thomas S. Churcher
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)
Abstract Transmission blocking vaccines (TBV) which aim to control malaria by inhibiting human-to-mosquito transmission show considerable promise though their utility against naturally circulating parasites remains unknown. The efficacy of two lead c
Externí odkaz:
https://doaj.org/article/3a91c7a83f314d7398ec266842b1ca4e
Autor:
Darren B. Leneghan, Kazutoyo Miura, Iona J. Taylor, Yuanyuan Li, Jing Jin, Karl D. Brune, Martin F. Bachmann, Mark Howarth, Carole A. Long, Sumi Biswas
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
Abstract Vaccine development efforts have recently focused on enabling strong immune responses to poorly immunogenic antigens, via display on multimerisation scaffolds or virus like particles (VLPs). Typically such studies demonstrate improved antibo
Externí odkaz:
https://doaj.org/article/af545a6db3a5422c9c7b0870d3c2cf54
Autor:
Pauline M. van Diemen, Darren B. Leneghan, Iona J. Brian, Kazutoyo Miura, Carole A. Long, Anita Milicic, Sumi Biswas, Christine S. Rollier, David H. Wyllie
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract A persistent goal of vaccine development is the enhancement of the immunogenicity of antigens while maintaining safety. One strategy involves alteration of the presentation of the antigen by combining antigens with a multimeric scaffold. Mul
Externí odkaz:
https://doaj.org/article/9486e757e39243498c51768ecb873839